Active Lymphoma Clinical Trials

Data from ClinicalTrials.gov · Privacy-First Design · No Account Required · No Health Data Stored

Why Consider a Lymphoma Clinical Trial?

• Find Trials That Fit — Browse recruiting Lymphoma trials pulled directly from ClinicalTrials.gov — updated continuously so you always see real, active studies.
• No Medical Jargon — Eligibility criteria are rewritten into plain yes-or-no questions. It's always okay to answer "not sure" — your doctor can help fill in the rest.
• See How Well You Match — Get a clear picture of how closely a trial fits your situation, so you know which ones are worth bringing to your oncologist.
• Ready for Your Appointment — Generate a printable or emailable summary for your next visit. A caregiver can send it to your doctor ahead of time.

How It Works

1. Share a Few Details — Enter your Lymphoma type, stage, and location. No personal health information is required or stored.
2. Answer Yes-or-No Questions — We rewrite complex eligibility criteria into plain language. "Not sure" is always a valid answer.
3. Bring Results to Your Doctor — Get a printable summary with the NCT ID, match assessment, and questions to ask your oncologist.

Free · No account · Nothing you enter is stored

Lymphoma Clinical Trial FAQ

What is CAR-T cell therapy, and is there a lymphoma trial for it?

CAR-T (chimeric antigen receptor T-cell) therapy involves collecting your own immune cells, genetically reprogramming them to attack lymphoma cells, and infusing them back. Several CAR-T products are FDA-approved for diffuse large B-cell lymphoma (DLBCL) and other subtypes. Clinical trials are testing next-generation CAR-T constructs, combination approaches, and CAR-T for additional lymphoma types.

Are there lymphoma trials for patients with relapsed or refractory disease?

Yes — relapsed/refractory lymphoma is one of the most researched areas in oncology. Trials are testing bispecific antibodies (like epcoritamab, mosunetuzumab), CAR-T therapies, antibody-drug conjugates, PI3K inhibitors, and novel combinations. The specific options depend on your lymphoma subtype and prior treatment history.

Do Hodgkin and non-Hodgkin lymphoma patients qualify for the same trials?

Usually not. Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) are biologically distinct, and most trials are specific to one or the other. Within NHL, further subtype specificity matters — DLBCL trials, follicular lymphoma trials, and mantle cell lymphoma trials typically enroll separately. Trialify helps you filter by your exact lymphoma subtype.

Can I join a lymphoma trial if I've already had a stem cell transplant?

Prior stem cell transplant (autologous or allogeneic) is acceptable for many trials and may even be an eligibility requirement for some. For allogeneic transplant recipients, the time since transplant, current immunosuppression levels, and graft-versus-host disease status often determine eligibility. Each trial protocol specifies these requirements.

How quickly do I need to enroll in a lymphoma trial after my cancer returns?

There is no universal deadline, but lymphoma can progress quickly, so acting promptly is often important. Enrollment processes typically take 2–6 weeks from initial contact to first treatment. Trialify helps you identify matching trials quickly so you can start the conversation with your oncologist as soon as possible.

Explore Other Cancer Trial Guides

• Diffuse Large B-Cell Lymphoma (DLBCL) — Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma. Trials are advancing CAR-T cell therapies (axi-cel, liso-cel, tisa-cel), bispecific antibodies (epcoritamab, glofitamab), and novel combinations for relapsed and refractory disease.
• Leukemia — Leukemia trials are testing targeted inhibitors, CAR-T therapies, and novel transplant strategies for AML, ALL, CLL, and CML. New treatment options are emerging rapidly across all leukemia types.
• Multiple Myeloma — Multiple myeloma trials are advancing CAR-T therapies, bispecific antibodies, BCMA-targeted agents, and novel triplet combinations — offering new paths for newly diagnosed and relapsed/refractory patients.
• Breast Cancer — Breast cancer trials are testing innovative therapies for all subtypes — HER2+, triple-negative (TNBC), and hormone receptor-positive. New options are opening every month at cancer centers across the country.